Toronto, ON – Biopharmaceutical company Lorus Therapeutics, that specializes in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, says that its subsidiary, GeneSense Technologies, has been allowed a patent by the Canadian Patent Office entitled “Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase.”
The patent protects Lorus’ antisense molecules that target R1 and R2, including its lead anticancer drugs in the clinic, GTI-2401 and GTI-2501.
GTI-2040 is currently the subject of a clinical trials agreement with the US National Cancer Institute (NCI) under which GTI-2040 is being tested in combination with chemotherapy in five different clinical trials. These include studies of GTI 2040 in breast, lung, colon, acute myeloid leukemia and a variety of solid tumors.
The company says the phase II interim clinical data arising from GTI-2040 in combination therapy for the treatment of renal cell carcinoma has provided evidence of disease stabilizations, tumour reductions and a favourable safety profile at the recommended phase II dose. Patients in the clinical study had previously failed or were ineligible for standard therapies, and were representative of a population with very poor prognostic outcome.
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer and a variety of other tumor types.